血管活性肽在自身免疫性疾病发生发展中的参与及作用
The Involvement and Role of Vasoactive Peptides in the Occurrence and Development of Autoimmune Diseases
DOI: 10.12677/pi.2024.134041, PDF,   
作者: 李佳琳, 戴 岳*：中国药科大学中药学院中药药理与中医药学系，江苏 南京
关键词: 血管活性肠肽；自身免疫性疾病；作用机制；Vasoactive Intestinal Peptide； Autoimmune Diseases； Mechanism of Action
摘要: 血管活性肠肽(vasoactive intestinal peptide, VIP)是一种主要存在于中枢神经系统和肠道神经系统的神经递质，在肠道神经系统主要由肠神经元释放，既是一种胃肠激素，又是一种具有多种功能的神经肽。VIP对多种自身免疫性疾病具有治疗潜力，包括类风湿性关节炎、炎症性肠病和干燥综合征等。本文总结VIP在多种自身免疫性疾病发生发展中的参与及作用，为上述疾病的治疗提供新思路。
Abstract: Vasoactive intestinal peptide (VIP) is a neurotransmitter primarily found in the central nervous system and the enteric nervous system. In the enteric nervous system, it is predominantly released by enteric neurons. It serves as both a gastrointestinal hormone and a neuropeptide with various functions. VIP holds therapeutic potential for several autoimmune diseases, including rheumatoid arthritis, inflammatory bowel disease, and Sjögren’s syndrome. This article summarizes the involvement and effects of VIP in the occurrence and development of multiple autoimmune diseases, providing new insights for the treatment of the aforementioned conditions.
文章引用：李佳琳, 戴岳. 血管活性肽在自身免疫性疾病发生发展中的参与及作用[J]. 药物资讯, 2024, 13(4): 355-361. https://doi.org/10.12677/pi.2024.134041

参考文献

[1] Simon, R.A., Barazanji, N., Jones, M.P., Bednarska, O., Icenhour, A., Engström, M., et al. (2021) Vasoactive Intestinal Polypeptide Plasma Levels Associated with Affective Symptoms and Brain Structure and Function in Healthy Females. Scientific Reports, 11, Article No. 1406. [Google Scholar] [CrossRef] [PubMed]
[2] Myers-Joseph, D., Wilmes, K.A., Fernandez-Otero, M., Clopath, C. and Khan, A.G. (2024) Disinhibition by VIP Interneurons Is Orthogonal to Cross-Modal Attentional Modulation in Primary Visual Cortex. Neuron, 112, 628-645.E7. [Google Scholar] [CrossRef] [PubMed]
[3] Paran, D., Elkayam, O., Mayo, A., et al. (2001) A Pilot Study of a Long Acting Somatostatin Analogue for the Treatment of Refractory Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 60, 888-891.
[4] Gonzalez-Rey, E., Varela, N., Sheibanie, A.F., Chorny, A., Ganea, D. and Delgado, M. (2006) Cortistatin, an Antiinflammatory Peptide with Therapeutic Action in Inflammatory Bowel Disease. Proceedings of the National Academy of Sciences of the United States of America, 103, 4228-4233. [Google Scholar] [CrossRef] [PubMed]
[5] Chandrasekharan, B., Nezami, B.G. and Srinivasan, S. (2013) Emerging Neuropeptide Targets in Inflammation: NPY and VIP. American Journal of Physiology-Gastrointestinal and Liver Physiology, 304, G949-G957. [Google Scholar] [CrossRef] [PubMed]
[6] Huang, J., Fu, X., Chen, X., Li, Z., Huang, Y. and Liang, C. (2021) Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis. Frontiers in Immunology, 12, Article 686155. [Google Scholar] [CrossRef] [PubMed]
[7] Brown, P., Pratt, A.G. and Hyrich, K.L. (2024) Therapeutic Advances in Rheumatoid Arthritis. BMJ, 384, e070856. [Google Scholar] [CrossRef] [PubMed]
[8] Martínez, C., Ortiz, A.M., Juarranz, Y., Lamana, A., Seoane, I.V., Leceta, J., et al. (2014) Serum Levels of Vasoactive Intestinal Peptide as a Prognostic Marker in Early Arthritis. PLOS ONE, 9, e85248. [Google Scholar] [CrossRef] [PubMed]
[9] Šteigerová, M., Šíma, M. and Slanař, O. (2023) Pathogenesis of Collagen-Induced Arthritis: Role of Immune Cells with Associated Cytokines and Antibodies, Comparison with Rheumatoid Arthritis. Folia Biologica, 69, 41-49. [Google Scholar] [CrossRef] [PubMed]
[10] Delgado, M., Abad, C., Martinez, C., Leceta, J. and Gomariz, R.P. (2001) Vasoactive Intestinal Peptide Prevents Experimental Arthritis by Downregulating Both Autoimmune and Inflammatory Components of the Disease. Nature Medicine, 7, 563-568. [Google Scholar] [CrossRef] [PubMed]
[11] Juarranz, Y., Abad, C., Martinez, C., et al. (2005) Protective Effect of Vasoactive Intestinal Peptide on Bone Destruction in the Collagen-Induced Arthritis Model of Rheumatoid Arthritis. Arthritis Research & Therapy, 7, R1034-R1045.
[12] Juarranz, M.G. (2004) Vasoactive Intestinal Peptide Modulates Proinflammatory Mediator Synthesis in Osteoarthritic and Rheumatoid Synovial Cells. Rheumatology, 43, 416-422. [Google Scholar] [CrossRef] [PubMed]
[13] Gutiérrez-Cañas, I., Juarranz, Y., Santiago, B., Martínez, C., Gomariz, R.P., Pablos, J.L., et al. (2008) Immunoregulatory Properties of Vasoactive Intestinal Peptide in Human T Cell Subsets: Implications for Rheumatoid Arthritis. Brain, Behavior, and Immunity, 22, 312-317. [Google Scholar] [CrossRef] [PubMed]
[14] Carrión, M., Pérez-García, S., Martínez, C., Juarranz, Y., Estrada-Capetillo, L., Puig-Kröger, A., et al. (2016) VIP Impairs Acquisition of the Macrophage Proinflammatory Polarization Profile. Journal of Leukocyte Biology, 100, 1385-1393. [Google Scholar] [CrossRef] [PubMed]
[15] Muschter, D., Schäfer, N., Stangl, H., Straub, R.H. and Grässel, S. (2015) Sympathetic Neurotransmitters Modulate Osteoclastogenesis and Osteoclast Activity in the Context of Collagen-Induced Arthritis. PLOS ONE, 10, e0139726. [Google Scholar] [CrossRef] [PubMed]
[16] Gilliland, A., Chan, J.J., De Wolfe, T.J., Yang, H. and Vallance, B.A. (2024) Pathobionts in Inflammatory Bowel Disease: Origins, Underlying Mechanisms, and Implications for Clinical Care. Gastroenterology, 166, 44-58. [Google Scholar] [CrossRef] [PubMed]
[17] Kubota, Y., Petras, R.E., Ottaway, C.A., Tubbs, R.R., Farmer, R.G. and Fiocchi, C. (1992) Colonic Vasoactive Intestinal Peptide Nerves in Inflammatory Bowel Disease. Gastroenterology, 102, 1242-1251. [Google Scholar] [CrossRef] 
[18] Sun, X., Guo, C., Zhao, F., Zhu, J., Xu, Y., Liu, Z., et al. (2019) Vasoactive Intestinal Peptide Stabilizes Intestinal Immune Homeostasis through Maintaining Interleukin-10 Expression in Regulatory B Cells. Theranostics, 9, 2800-2811. [Google Scholar] [CrossRef] [PubMed]
[19] Wu, X., Conlin, V.S., Morampudi, V., Ryz, N.R., Nasser, Y., Bhinder, G., et al. (2015) Vasoactive Intestinal Polypeptide Promotes Intestinal Barrier Homeostasis and Protection against Colitis in Mice. PLOS ONE, 10, e0125225. [Google Scholar] [CrossRef] [PubMed]
[20] Abad, C., Martinez, C., Juarranz, M.G., Arranz, A., Leceta, J., Delgado, M., et al. (2003) Therapeutic Effects of Vasoactive Intestinal Peptide in the Trinitrobenzene Sulfonic Acid Mice Model of Crohn’s Disease. Gastroenterology, 124, 961-971. [Google Scholar] [CrossRef] [PubMed]
[21] Conlin, V.S., Wu, X., Nguyen, C., Dai, C., Vallance, B.A., Buchan, A.M.J., et al. (2009) Vasoactive Intestinal Peptide Ameliorates Intestinal Barrier Disruption Associated with Citrobacter rodentium-Induced Colitis. American Journal of Physiology-Gastrointestinal and Liver Physiology, 297, G735-G750. [Google Scholar] [CrossRef] [PubMed]
[22] Villanueva-Romero, R., Gutiérrez-Cañas, I., Carrión, M., Pérez-García, S., Seoane, I.V., Martínez, C., et al. (2018) The Anti-Inflammatory Mediator, Vasoactive Intestinal Peptide, Modulates the Differentiation and Function of Th Subsets in Rheumatoid Arthritis. Journal of Immunology Research, 2018, Article ID: 6043710. [Google Scholar] [CrossRef] [PubMed]
[23] Beydon, M., McCoy, S., Nguyen, Y., Sumida, T., Mariette, X. and Seror, R. (2023) Epidemiology of Sjögren syndrome. Nature Reviews Rheumatology, 20, 158-169. [Google Scholar] [CrossRef] [PubMed]
[24] Törnwall, J., Uusitalo, H., Hukkanen, M., et al. (1994) Distribution of Vasoactive Intestinal Peptide (VIP) and Its Binding Sites in Labial Salivary Glands in Sjögren’s Syndrome and in Normal Controls. Clinical and Experimental Rheumatology, 12, 287-292.
[25] Cha, S., Peck, A.B. and Humphreys-Beher, M.G. (2002) Progress in Understanding Autoimmune Exocrinopathy Using The Non-Obese Diabetic Mouse: An Update. Critical Reviews in Oral Biology & Medicine, 13, 5-16. [Google Scholar] [CrossRef] [PubMed]
[26] Groneberg, D.A., Springer, J. and Fischer, A. (2001) Vasoactive Intestinal Polypeptide as Mediator of Asthma. Pulmonary Pharmacology & Therapeutics, 14, 391-401. [Google Scholar] [CrossRef] [PubMed]
[27] Li, C., Zhu, F., Wu, B. and Wang, Y. (2017) Vasoactive Intestinal Peptide Protects Salivary Glands against Structural Injury and Secretory Dysfunction via IL-17A and AQP5 Regulation in a Model of Sjögren Syndrome. Neuroimmunomodulation, 24, 300-309. [Google Scholar] [CrossRef] [PubMed]
[28] Lodde, B.M. (2006) Effect of Human Vasoactive Intestinal Peptide Gene Transfer in a Murine Model of Sjogren’s Syndrome. Annals of the Rheumatic Diseases, 65, 195-200. [Google Scholar] [CrossRef] [PubMed]
[29] Li, Y., Zhu, W., Lin, R., Zhao, J. and Wang, Y. (2023) Vasoactive Intestinal Peptide Exerts Therapeutic Action by Regulating PTEN in a Model of Sjögren’s Disease. Immunity, Inflammation and Disease, 11, e936. [Google Scholar] [CrossRef] [PubMed]
[30] Jakimovski, D., Bittner, S., Zivadinov, R., Morrow, S.A., Benedict, R.H., Zipp, F., et al. (2024) Multiple Sclerosis. The Lancet, 403, 183-202. [Google Scholar] [CrossRef] [PubMed]
[31] Al-Keilani, M.S., Almomani, B.A., Al-Sawalha, N.A., Al Qawasmeh, M. and Jaradat, S.A. (2021) Significance of Serum VIP and PACAP in Multiple Sclerosis: An Exploratory Case-Control Study. Neurological Sciences, 43, 2621-2630. [Google Scholar] [CrossRef] [PubMed]
[32] Baranowska-Bik, A., Kochanowski, J., Uchman, D., Wolinska-Witort, E., Kalisz, M., Martynska, L., et al. (2013) Vasoactive Intestinal Peptide (VIP) and Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) in Humans with Multiple Sclerosis. Journal of Neuroimmunology, 263, 159-161. [Google Scholar] [CrossRef] [PubMed]
[33] Cobo, M., Anderson, P., Benabdellah, K., Toscano, M.G., Muñoz, P., García-Pérez, A., et al. (2013) Mesenchymal Stem Cells Expressing Vasoactive Intestinal Peptide Ameliorate Symptoms in a Model of Chronic Multiple Sclerosis. Cell Transplantation, 22, 839-854. [Google Scholar] [CrossRef] [PubMed]
[34] Fernandez‐Martin, A., Gonzalez‐Rey, E., Chorny, A., Ganea, D. and Delgado, M. (2006) Vasoactive Intestinal Peptide Induces Regulatory T Cells during Experimental Autoimmune Encephalomyelitis. European Journal of Immunology, 36, 318-326. [Google Scholar] [CrossRef] [PubMed]
[35] Rapaport, R. (2024) Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America, 53, xv-xvi. [Google Scholar] [CrossRef] [PubMed]
[36] Jimeno, R., Gomariz, R.P., Gutiérrez‐Cañas, I., Martínez, C., Juarranz, Y. and Leceta, J. (2010) New Insights into the Role of VIP on the Ratio of T‐Cell Subsets during the Development of Autoimmune Diabetes. Immunology & Cell Biology, 88, 734-745. [Google Scholar] [CrossRef] [PubMed]
[37] Martin, B., Shin, Y., White, C.M., Ji, S., Kim, W., Carlson, O.D., et al. (2010) Vasoactive Intestinal Peptide–null Mice Demonstrate Enhanced Sweet Taste Preference, Dysglycemia, and Reduced Taste Bud Leptin Receptor Expression. Diabetes, 59, 1143-1152. [Google Scholar] [CrossRef] [PubMed]
[38] Kato, I., Suzuki, Y., Akabane, A., Yonekura, H., Tanaka, O., Kondo, H., et al. (1994) Transgenic Mice Overexpressing Human Vasoactive Intestinal Peptide (VIP) Gene in Pancreatic Beta Cells. Evidence for Improved Glucose Tolerance and Enhanced Insulin Secretion by VIP and PHM-27 in Vivo. Journal of Biological Chemistry, 269, 21223-21228. [Google Scholar] [CrossRef] [PubMed]
[39] Fanouriakis, A., Kostopoulou, M., Andersen, J., Aringer, M., Arnaud, L., Bae, S., et al. (2023) EULAR Recommendations for the Management of Systemic Lupus Erythematosus: 2023 Update. Annals of the Rheumatic Diseases, 83, 15-29. [Google Scholar] [CrossRef] [PubMed]
[40] Fu, D., Senouthai, S., Wang, J. and You, Y. (2019) Vasoactive Intestinal Peptide Ameliorates Renal Injury in a Pristane-Induced Lupus Mouse Model by Modulating Th17/Treg Balance. BMC Nephrology, 20, Article No. 350. [Google Scholar] [CrossRef] [PubMed]
[41] Bloom, S.R., Polak, J. and Pearse, A.G.E. (1973) Vasoactive Intestinal Peptide and Watery-Diarrhœa Syndrome. The Lancet, 302, 14-16. [Google Scholar] [CrossRef] [PubMed]
[42] Fernandez-Montesinos, R., Castillo, P.M., Klippstein, R., Gonzalez-Rey, E., Mejias, J.A., Zaderenko, A.P., et al. (2009) Chemical Synthesis and Characterization of Silver-Protected Vasoactive Intestinal Peptide Nanoparticles. Nanomedicine, 4, 919-930. [Google Scholar] [CrossRef] [PubMed]
[43] Masaka, T., Li, Y., Kawatobi, S., Koide, Y., Takami, A., Yano, K., et al. (2014) Liposome Modified with VIP-Lipopeptide as a New Drug Delivery System. Yakugaku Zasshi, 134, 987-995. [Google Scholar] [CrossRef] [PubMed]
[44] Olson, K.E., Kosloski-Bilek, L.M., Anderson, K.M., Diggs, B.J., Clark, B.E., Gledhill, J.M., et al. (2015) Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in MPTP-Intoxicated Mice. The Journal of Neuroscience, 35, 16463-16478. [Google Scholar] [CrossRef] [PubMed]
[45] Seoane, I.V., Ortiz, A.M., Piris, L., Lamana, A., Juarranz, Y., García-Vicuña, R., et al. (2016) Clinical Relevance of VPAC1 Receptor Expression in Early Arthritis: Association with IL-6 and Disease Activity. PLOS ONE, 11, e0149141. [Google Scholar] [CrossRef] [PubMed]
[46] Sun, W., Hong, J., Zang, Y.C.Q., Liu, X. and Zhang, J.Z. (2006) Altered Expression of Vasoactive Intestinal Peptide Receptors in T Lymphocytes and Aberrant Th1 Immunity in Multiple Sclerosis. International Immunology, 18, 1691-1700. [Google Scholar] [CrossRef] [PubMed]